Short Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Decreases By 7.1%

Werewolf Therapeutics, Inc. (NASDAQ:HOWLGet Free Report) was the target of a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 432,000 shares, a drop of 7.1% from the February 29th total of 464,800 shares. Based on an average trading volume of 255,100 shares, the short-interest ratio is currently 1.7 days. Approximately 1.6% of the company’s shares are short sold.

Werewolf Therapeutics Stock Down 5.0 %

Shares of NASDAQ:HOWL opened at $6.06 on Wednesday. The company has a quick ratio of 7.14, a current ratio of 7.14 and a debt-to-equity ratio of 0.29. The company has a 50-day moving average price of $6.20 and a 200-day moving average price of $4.08. Werewolf Therapeutics has a 12 month low of $1.57 and a 12 month high of $8.19.

Werewolf Therapeutics (NASDAQ:HOWLGet Free Report) last posted its earnings results on Thursday, March 7th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.10. The firm had revenue of $1.50 million for the quarter, compared to analysts’ expectations of $2.75 million. Werewolf Therapeutics had a negative return on equity of 32.25% and a negative net margin of 187.37%. Equities research analysts expect that Werewolf Therapeutics will post -1.38 earnings per share for the current year.

Institutional Trading of Werewolf Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its position in shares of Werewolf Therapeutics by 59.5% during the fourth quarter. Vanguard Group Inc. now owns 873,438 shares of the company’s stock valued at $3,371,000 after purchasing an additional 325,787 shares in the last quarter. Virtu Financial LLC purchased a new position in Werewolf Therapeutics during the fourth quarter valued at $79,000. PFM Health Sciences LP boosted its holdings in shares of Werewolf Therapeutics by 35.6% during the 4th quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company’s stock valued at $13,387,000 after buying an additional 909,895 shares in the last quarter. Lighthouse Investment Partners LLC purchased a new stake in shares of Werewolf Therapeutics in the 4th quarter worth about $87,000. Finally, Northern Trust Corp lifted its position in Werewolf Therapeutics by 90.5% during the 4th quarter. Northern Trust Corp now owns 49,648 shares of the company’s stock valued at $192,000 after acquiring an additional 23,581 shares during the period. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

Werewolf Therapeutics Company Profile

(Get Free Report)

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.

See Also

Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with's FREE daily email newsletter.